ResMed Inc. (RMD) - Q3 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026 (Q3 of Fiscal Year 2026). ResMed Inc. is a global leader in medical devices and cloud-based software for diagnosing and treating sleep-disordered breathing and respiratory disorders. The company operates two primary segments: Sleep and Breathing Health (devices and masks) and Residential Care Software (SaaS platforms for home care providers).
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $1,431.4 million | $1,291.7 million | $4,189.8 million | $3,798.3 million |
| Gross Profit | $891.0 million | $766.4 million | $2,590.5 million | $2,234.9 million |
| Gross Margin | 62.2% | 59.3% | 61.8% | 58.8% |
| Operating Income | $499.8 million | $426.3 million | $1,438.0 million | $1,230.8 million |
| Net Income | $398.7 million | $365.0 million | $1,139.9 million | $1,021.0 million |
| Diluted EPS | $2.74 | $2.48 | $7.79 | $6.93 |
| Cash & Equivalents | $1,660.5 million (as of Mar 31, 2026) | |||
| Operating Cash Flow (YTD) | $1,351.2 million | $1,212.8 million | ||
| Total Debt | $664.1 million (as of Mar 31, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 11% year-over-year (YoY) for Q3 and 10% YoY for the nine-month period. On a constant currency basis, growth was 8% for both periods, driven by increased unit sales of devices and masks globally.
- Margin Expansion: Gross margin improved to 62.2% in Q3 (from 59.3% prior year) due to manufacturing/logistics efficiencies and component cost improvements.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 16% in Q3, partly due to foreign currency impacts ($13.0M) and $5.9M in acquisition/portfolio review charges. R&D expenses increased 12% primarily due to employee-related costs.
- Restructuring: The company recorded $21.7 million in restructuring charges during the nine months ended March 31, 2026, related to workforce planning. No restructuring expenses were recorded in the prior year period.
- Debt Reduction: Total debt decreased slightly to $664.1 million from $668.3 million at the end of the prior fiscal year. Interest income turned positive ($12.3M in Q3) due to lower debt levels and gains on hedging instruments.
Outlook, Risks, and Unusual Items
- Guidance: The filing does not contain specific numerical forward-looking guidance for the full fiscal year 2026. Management expects cash from operations to fund operations and capital expenditures for the next 12 months.
- Share Repurchases: The company repurchased $500.0 million of treasury stock during the nine months ended March 31, 2026. Approximately 8.9 million shares remain available under the current program.
- Dividends: A quarterly dividend of $0.60 per share was declared for Q3. A subsequent dividend of $0.60 per share was declared on April 30, 2026.
- Legal Proceedings:
- NYU Litigation: Dismissed with prejudice in November 2025 after the Federal Circuit affirmed patent invalidity.
- Cleveland Medical: Multiple patent infringement suits are ongoing. PTAB proceedings are pending for several patents, with final decisions expected by July 2026.
- Fractus: A new patent infringement suit filed in October 2025 regarding antenna technology; a motion to dismiss is pending.
- Whistleblower Complaint: An unsealed False Claims Act complaint regarding CPAP sales to the VA was noted; the company has not been served and cannot estimate potential loss.
- Tax Risks: The effective tax rate increased to 20.6% in Q3 (from 12.6% prior year) due to the implementation of global minimum taxes (Pillar Two) and the absence of prior-year IRS refunds.
Investor Verification Checklist
- Constant Currency Growth: Verify the 8% constant currency revenue growth rate to assess organic performance excluding FX benefits.
- Restructuring Impact: Confirm the $21.7M restructuring charge is fully accrued and assess the remaining $1.6M accrual for future cash outflows.
- Legal Exposure: Monitor the status of the Cleveland Medical and Fractus patent litigation, as outcomes could impact future product sales or require royalty payments.
- Debt Covenants: Verify continued compliance with the 3.50:1 funded debt to EBITDA covenant under the Senior Notes agreement.
- Non-GAAP Reconciliation: Review the reconciliation of Non-GAAP EPS ($2.86) vs. GAAP EPS ($2.74) to understand the impact of amortization and acquisition costs on reported earnings.